

[Tiotropium bromide](#)

Statut de médicament essentiel

Section:

[25. Medicines acting on the respiratory tract](#) [25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease](#)

Codes ATC: [R03BB04](#)

Indication

Chronic obstructive pulmonary disease Code ICD11: [CA22](#)

INN

Tiotropium bromide

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

Respiratory > Inhalation > powder: 18 µg in capsule

Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler ; 2.5 µg per actuation in soft mist inhaler

Historique des statuts LME

Ajouté pour la première fois en 2019 ([TRS 1021](#))

Modifié en 2021 ([TRS 1035](#))

Modifié en 2025 ([TRS 1064](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

[aclidinium](#) (Codes ATC: [R03BB05](#))

[glycopyrronium](#) (Codes ATC: [R03BB06](#))

[umeclidinium](#) (Codes ATC: [R03BB07](#))

Renseignements sur le brevet

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Lire la suite [sur les brevets](#).

Wikipédia

[Tiotropium bromide](#)

DrugBank

[Tiotropium bromide \(Tiotropium\)](#)

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes to the listing of tiotropium on the EML: - update the listing description of inhalation delivery systems for consistency across the Model Lists and to better reflect product characteristics.